Cotargeting polo-like kinase 1 and the Wnt/β-catenin signaling pathway in castration-resistant prostate cancer

Molecular and Cellular Biology

Volumn 35, Issue 24, 2015, Pages 4185-4198

  Li, Jie ^a   Karki, Anju ^b   Hodges, Kurt B ^c   Ahmad, Nihal ^d   Zoubeidi, Amina ^e   Strebhardt, Klaus ^f   Ratliff, Timothy L ^g   Konieczny, Stephen F ^b,g   Liu, Xiaoqi ^g  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e VANCOUVER PROSTATE CENTRE   (Canada)

^f GOETHE UNIVERSITY   (Germany)

^g Purdue University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; BETA CATENIN; CELL CYCLE PROTEIN 20; GLYCOGEN SYNTHASE KINASE 3; POLO LIKE KINASE 1; ANTIMITOTIC AGENT; AXIN; AXIN2 PROTEIN, HUMAN; CDC20 PROTEIN, HUMAN; CELL CYCLE PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; GSK3B PROTEIN, HUMAN; GSK3B PROTEIN, MOUSE; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE; PTERIDINE DERIVATIVE; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL CULTURE; CONTROLLED STUDY; CYTOSOL; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; WNT SIGNALING PATHWAY; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; DRUG EFFECTS; HEK293 CELL LINE; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIMITOTIC AGENTS; AXIN PROTEIN; BETA CATENIN; CDC20 PROTEINS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HEK293 CELLS; HUMANS; MALE; MICE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; TRANSPLANTATION, HETEROLOGOUS; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84949661232     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00825-15     Document Type: Article

References (46)

1. Schrijvers D, Van Erps P, Cortvriend J. 2010. Castration-refractory prostate cancer: new drugs in the pipeline. Adv Ther 27:285-296. http://dx.doi.org/10.1007/s12325-010-0038-1.
2. Saad F. 2013. Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer. Ther Adv Urol 5:201-210. http://dx.doi.org/10.1177/1756287213490054.
3. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B. 2014. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424-433. http://dx.doi.org/10.1056/NEJMoa1405095.
4. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. 2013. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138-148. http://dx.doi.org/10.1056/NEJMoa1209096.
5. Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. 2014. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 66:815-825. http://dx.doi.org/10.1016/j.eururo.2014.02.056.
6. Ryan CJ, Molina A, Griffin T. 2013. Abiraterone in metastatic prostate cancer.N Engl J Med 368:1458-1459. http://dx.doi.org/10.1056/NEJMc1301594.
7. Clevers H, Nusse R. 2012. Wnt/beta-catenin signaling and disease. Cell 149:1192-1205. http://dx.doi.org/10.1016/j.cell.2012.05.012.
8. Yokoyama NN, Shao S, Hoang BH, Mercola D, Zi X. 2014. Wnt signaling in castration-resistant prostate cancer: implications for therapy. Am J Clin Exp Urol 2:27-44.
9. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA. 2012. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487:239-243. http://dx.doi.org/10.1038/nature11125.
10. Weichert W, Schmidt M, Gekeler V, Denkert C, Stephan C, Jung K, Loening S, Dietel M, Kristiansen G. 2004. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 60:240-245. http://dx.doi.org/10.1002/pros.20050.
11. Strebhardt K, Ullrich A. 2006. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6:321-330. http://dx.doi.org/10.1038/nrc1841.
12. Sun Y, Wang B-E, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, Settleman J, Johnson L. 2012. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res 72:527-536. http://dx.doi.org/10.1158/0008-5472.CAN-11-3004.
13. Russo MA, Kang KS, Di Cristofano A. 2013. The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations. Thyroid 23:1284-1293. http://dx.doi.org/10.1089/thy.2013.0037.
14. Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M, Gurtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, Peters JM, Rettig WJ. 2007. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17:316-322. http://dx.doi.org/10.1016/j.cub.2006.12.037.
15. Zhang Z, Hou X, Shao C, Li J, Cheng JX, Kuang S, Ahmad N, Ratliff T, Liu X. 2014. Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer. Cancer Res 74:6635-6647.http://dx.doi.org/10.1158/0008-5472.CAN-14-1916.
16. Song B, Liu XS, Davis K, Liu X. 2011. Plk1 phosphorylation of Orc2 promotes DNA replication under conditions of stress. Mol Cell Biol 31: 4844-4856. http://dx.doi.org/10.1128/MCB.06110-11.
17. Liu X, Lei M, Erikson RL. 2006. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 26:2093-2108. http://dx.doi.org/10.1128/MCB.26.6.2093-2108.2006.
18. Liu X, Erikson RL. 2003. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A 100:5789-5794. http://dx.doi.org/10.1073/pnas.1031523100.
19. Dai D, Holmes AM, Nguyen T, Davies S, Theele DP, Verschraegen C, Leslie KK. 2005. A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer. Cancer Res 65:9517-9524. http://dx.doi.org/10.1158/0008-5472.CAN-05-1613.
20. Chou TC, Talalay P. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55. http://dx.doi.org/10.1016/0065-2571(84)90007-4.
21. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS. 1997. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18:1215-1223. http://dx.doi.org/10.1093/carcin/18.6.1215.
22. Raab M, Kappel S, Kramer A, Sanhaji M, Matthess Y, Kurunci-Csacsko E, Calzada-Wack J, Rathkolb B, Rozman J, Adler T, Busch DH, Esposito I, Fuchs H, Gailus-Durner V, Klingenspor M, Wolf E, Sanger N, Prinz F, Angelis MH, Seibler J, Yuan J, Bergmann M, Knecht R, Kreft B, Strebhardt K. 2011. Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nat Commun 2:395. http://dx.doi.org/10.1038/ncomms1395.
23. Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, Briere D, Los G, Gleave M, Fanjul A, Zoubeidi A. 2013. A novel antiandrogen, compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.MolCancer Ther 12:567-576.http://dx.doi.org/10.1158/1535-7163.MCT-12-0798.
24. Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, Hassler DF, Smith GK, Gontarek RR, Courtney MP, Sutton D, Diamond MA, Jackson JR, Laquerre SG. 2009. Distinct concentrationdependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res 69: 6969-6977. http://dx.doi.org/10.1158/0008-5472.CAN-09-0945.
25. Yim H. 2013. Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Anticancer Drugs 24:999-1006. http://dx.doi.org/10.1097/CAD.0000000000000007.
26. Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, Vessella RL. 2003. LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate 55:239-246. http://dx.doi.org/10.1002/pros.10198.
27. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB. 2011. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17:5913-5925. http://dx.doi.org/10.1158/1078-0432.CCR-11-0728.
28. Iliuk A, Liu XS, Xue L, Liu X, Tao WA. 2012. Chemical visualization of phosphoproteomes on membrane. Mol Cell Proteomics 11:629-639. http://dx.doi.org/10.1074/mcp.O112.018010.
29. MacDonald BT, Tamai K, He X. 2009. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17:9-26. http://dx.doi.org/10.1016/j.devcel.2009.06.016.
30. Lee E, Madar A, David G, Garabedian MJ, Dasgupta R, Logan SK. 2013. Inhibition of androgen receptor and beta-catenin activity in prostate cancer. Proc Natl Acad SciUSA110:15710-15715. http://dx.doi.org/10.1073/pnas.1218168110.
31. Truica CI, Byers S, Gelmann EP. 2000. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 60: 4709-4713.
32. Verras M, Brown J, Li X, Nusse R, Sun Z. 2004. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res 64:8860-8866. http://dx.doi.org/10.1158/0008-5472.CAN-04-2370.
33. Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG. 2004. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 279:19191-19200. http://dx.doi.org/10.1074/jbc.M309560200.
34. Sharma M, Chuang WW, Sun Z. 2002. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J Biol Chem 277:30935-30941. http://dx.doi.org/10.1074/jbc.M201919200.
35. Wang L, Lin HK, Hu YC, Xie S, Yang L, Chang C. 2004. Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells. J Biol Chem 279:32444-32452. http://dx.doi.org/10.1074/jbc.M313963200.
36. Hadjihannas MV, Bernkopf DB, Bruckner M, Behrens J. 2012. Cell cycle control of Wnt/beta-catenin signalling by conductin/axin2 through CDC20. EMBO Rep 13:347-354. http://dx.doi.org/10.1038/embor.2012.12.
37. Li H, Liu XS, Yang X, Wang Y, Wang Y, Turner JR, Liu X. 2010. Phosphorylation of CLIP-170 by Plk1 and CK2 promotes timely formation of kinetochore-microtubule attachments. EMBO J 29:2953-2965. http://dx.doi.org/10.1038/emboj.2010.174.
38. Li H, Liu XS, Yang X, Song B, Wang Y, Liu X. 2010. Polo-like kinase 1 phosphorylation of p150Glued facilitates nuclear envelope breakdown during prophase. Proc Natl Acad Sci U S A 107:14633-14638. http://dx.doi.org/10.1073/pnas.1006615107.
39. Hou X, Li Z, Huang W, Li J, Staiger C, Kuang S, Ratliff T, Liu X. 2013. Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer. Prostate 73:1352-1363. http://dx.doi.org/10.1002/pros.22683.
40. Li Z, Li J, Bi P, Lu Y, Burcham G, Elzey BD, Ratliff T, Konieczny SF, Ahmad N, Kuang S, Liu X. 2014. Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state. Mol Cell Biol 34:3642-3661. http://dx.doi.org/10.1128/MCB.00814-14.
41. Liu X. 2015. Targeting Polo-like kinases: a promising therapeutic approach for cancer treatment. Transl Oncol 8:185-195. http://dx.doi.org/10.1016/j.tranon.2015.03.010.
42. Liu XS, Li H, Song B, Liu X. 2010. Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery.EMBORep 11:626-632. http://dx.doi.org/10.1038/embor.2010.90.
43. Yang X, Li H, Liu XS, Deng A, Liu X. 2009. Cdc2-mediated phosphorylation of CLIP-170 is essential for its inhibition of centrosome reduplication. J Biol Chem 284:28775-28782. http://dx.doi.org/10.1074/jbc.M109.017681.
44. Song B, Liu XS, Rice SJ, Kuang S, Elzey BD, Konieczny SF, Ratliff TL, Hazbun T, Chiorean EG, Liu X. 2013. Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer. Mol Cancer Ther 12:58-68. http://dx.doi.org/10.1158/1535-7163.MCT-12-0632.
45. Ruan K, Ye F, Li C, Liou YC, Lin SC, Lin SY. 2012. PLK1 interacts and phosphorylates Axin that is essential for proper centrosome formation. PLoS One 7:e49184. http://dx.doi.org/10.1371/journal.pone.0049184.
46. Mbom BC, Siemers KA, Ostrowski MA, Nelson WJ, Barth AI. 2014. Nek2 phosphorylates and stabilizes beta-catenin at mitotic centrosomes downstream of Plk1. Mol Biol Cell 25:977-991. http://dx.doi.org/10.1091/mbc.E13-06-0349.